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Summary: In those cases where hypertriglyceridaemia was present before renal transplantation, it persisted
after transplantation, and hypercholesterolaemia also developed. We studied serum lipid, lipoprotein, and
apolipoprotein concentrations and plasma fibronectin concentrations in 57 renal transplantation patients and
29 healthy controls. We concluded that atherosclerosis in renal transplantation patients might be related to
alterations in the constitutions of lipoproteins and apolipoproteins, but fibronectin synthesized by vascular
endothelial cells seemed not to be associated with the atherosclerotic process.
Introduction
Cardiovascular disturbances are often observed in
chronic renal insufficiency, and coronary heart disease
is one of the most common causes of death in patients
with chronic renal failure (1, 2). In those cases where
atherosclerosis was present before renal transplanta-
tion, it persisted after transplantation (3). In these
patients, dyslipoproteinaemia is common (2, 4, 5). In
addition, hypertension, hyperuricaemia, alterations in
carbohydrate metabolism, and secondary hpyerpara-
thyroidism are contributory factors (2, 6). In chronic
renal failure, increased serum triacylglycerol concen-
trations, decreased serum high density lipoprotein
(HDL) cholesterol concentrations, and normal or
slightly elevated plasma cholesterol concentrations are
observed (2, 6, 7). In those cases where hypertrigly-
ceridaemia is present before renal transplantation, it
persists after transplantation, and hypercholesterolae-
mia also develops (8). During the last 10 years, more
studies have been reported on the apoproteins of the
lipoproteins. Lipoprotein abnormalities are common
in renal transplantation patients, but little attention
has been paid to the corresponding apolipoproteins.
In this study, we compared the serum lipoprotein and
apolipoprotein concentrations of renal transplanta-
tion patients with those of the controls. In addition,
we investigated the possible relation of these with
fibronectin, a plasma glycoprotein which had been
shown to be decreased in uraemic patients (9).
Materials and Methods
The study group was made up of 57 renal transplantation
patients (41 males and 16 females, mean age: 40.5 ± 13.8 years;
mean time after transplantation 28.6 ± 12.9 months) and the
control group was made up of 29 healthy volunteers (13 males
and 16 females, mean age: 30.0 + 6.8 years). Body mass indices
were 20.1 ± 2.9 kg/m2 for the study group and 21.9 ± 2.4
kg/m2 for the control group. The creatinine clearance of the
study group was 56.5 ± 18.4 ml/min, and that of the control
group was 115.5 ± 12.6 ml/min. For immunosuppression 0.5 —
1.5 mg/kg · d azathioprine was administered on the first, third,
eighth and fifteenth day after transplantation; prednisolone was
given in doses of 100 mg, 50 mg, 30 mg and 20 mg on the first,
third, eighth and fifteenth day, respectively. Appropriate doses
of cyclosporin A were administered to maintain a plasma con-
centration of 100 — 200 g/l. All analyses were performed on
blood samples taken from the ante-bracheal vein after a 12-
hour fast. Serum was separated immediately and kept at
— 38 °C until analysis. Fibronectin is lost during coagulation,
so that fibronectin analysis in serum is less valuable than in
plasma. Citrated plasma was used for fibronectin analysis.
Serum total cholesterol and triacylglycerol concentrations were
determined enzymatically on an automated Technicon RA-XT
system. HDL cholesterol was determined in the supernatant
after precipitation with phosphotungstate and MgQ2. Low
density lipoprotein (LDL) cholesterol and very low density
(VLDL) cholesterol were calculated by the Friedewald formula.
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Radial immunodiffusion plates were used for the determination
of apolipoproteins A, A-I, B and fibronectin (Behringwerke
AG, Marburg, Germany). Apolipoprotein C-II, C-III, E deter-
minations were performed by single radial immunodiffusion
(Daiichi Pharmaceutical Co., Tokyo, Japan). Student's t-test
was used for the statistical analyses.
Results
Results are shown in table 1. Serum total cholesterol
and triacylglycerol concentrations were increased in
renal transplantation patients compared with those of
the controls, and the difference between the two
groups was statistically significant (p < 0.001). Apo-
lipoprotein A concentrations, and apolipoprotein A/
apolipoprotein B ratio were significantly increased in
the transplantation group compared with those of the
Tab. 1. Serum lipid and apolipoprotein concentrations in renal
transplant patients and control subjects (mean + SD)
Cholesterol(g/D
HDL cholesterol
(g/1)
Triacylglycerols
(g/1)
Apolipoprotein A
(g/1)
Apolipoprotein A-I
(g/1)
Apolipoprotein B
(g/D
Apolipoprotein A/
Apolipoprotein B
Apolipoprotein A-I/
Apolipoprotein B
Apolipoprotein C-II
(g/1)
Apolipoprotein C-III
(g/1)
Apolipoprotein C-II/
Apolipoprotein C-III
Apolipoprotein E
(g/1)
Fibronectin
(g/1)
Trans-
plantation
(n = 57)
2.32 ± 0.49a
0.45 ±0.11
1.76 ± 0.89a
3.61 ± 0.82a
2.48 ± 0.66
1.71 ± 0.45a
2.21 ± 0.64b
1.53 ± 0.55C
0.06 ± 0.02a
0.23 ± 0.09a
0.27 ± 0.07a
0.07 ± 0.03a
0.33 ± 0.09
Control
(n = 29)
1.76 ± 0.29d
0.47 ± 0.12
0.92 ± 0.33
2.32 ± 0.62
2.26 ± 0.57
1.32 ± 0.31
1.76 ± 0.55
1.84 ± 0.72
0.04 ± 0.01
0.11 ± 0.03
0.39 ± 0.08
0.04 ± 0.02
0.35 ± 0.08
a
 < 0.001 0.001 < b < 0.01 0.02 < c < 0.05
d
 In a study performed by A. Azezli et al. the average of the
serum total cholesterol concentrations of healthy Turkish
subjects was found to be 1.65 ± 0.03 g/1. The study contained
10625 subjects and was reported in the XV. National Con-
gress of Endocrinology in Izmir in 1991 (31).
control group (p < 0.001). Apolipoprotein C-II and
apolipoprotein E concentrations were increased, and
the apolipoprotein C-II/apolipoprotein C-III ratio
was significantly decreased in the renal transplanta-
tion group (p < 0.001). There was no difference in
fibronectin concentrations between the two groups.
The correlation of fibronectin with lipids and lipo-
proteins was investigated in both groups and a mod-
erate correlation was found between fibronectin and
apolipoprotein C-II in the control group.
Discussion
Cardiovascular disturbances are frequent in chronic
renal insufficiency (1, 3). It has been reported that if
atherosclerosis has begun before transplantation, it
then continues to develop after renal transplantation
(3). Hypertriglyceridaemia is present in the majority
of patients who are uraemic or on maintenance di-
alysis; it persists after transplantation, together with
the development of hypercholesterolaemia (8). Lipo-
protein disturbances are common both in chronic
renal insufficiency and in renal transplant patients,
but few studies have been reported on apolipoproteins
in transplant patients. Total cholesterol, HDL choles-
terol and apolipoprotein A have been reported to be
high in patients with renal transplants (10, 11). Some
investigators have reported that HDL cholesterol con-
centrations were normal or decreased (12, 13). We
found that serum total cholesterol and apolipoprotein
A concentrations were increased in renal transplant
patients compared with those of the control group.
We found no difference in HDL cholesterol concen-
trations between the two groups.
Apolipoprotein A and apolipoprotein A-I are the
main protein components of HDL (14,15). We found
that there was no difference in serum apolipoprotein
A-I concentrations between transplant patients and
the control group. The present study shows a decrease
in the serum apolipoprotein A-I/apolipoprotein B ra-
tio and an increase in serum apolipoprotein A con-
centrations. Thus, hypercholesterolaemia and pre-
mature cardiovascular disease can be explained by the
changes in the composition of apolipoprotein A and
apolipoprotein A-I, which are major apolipoproteins
of HDL.
Hyperlipidaemia, which is common in dialysis pa-
tients, often persists after renal transplantation in
spite of a return to normal renal function. Cortico-
steroid immunosuppression has been suggested as a
cause of these lipid abnormalities. The importance of
hyperlipidaemia after transplantation is that it is the
major cause of death after renal transplantation (16).
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In vitro studies have also shown that corticosteroids
disturb the uptake of normal LDL cholesterol parti-
cles by the receptors (17). Thus, LDL cholesterol
metabolism in renal transplant patients is different
from that in normal subjects. Immunosuppression
regimens using low-dose prednisolone do not cause
hyperlipidaemia. In contrast, immunosuppression
with cyclosporin, either alone or with prednisolone,
gives rise to a significant increase in LDL cholesterol
in the first three months after transplantation. The
mechanism of this is not known and it is not due to
impairment of renal function by cyclosporin, but it
may be related to the transport of cyclosporin by
plasma lipoproteins. If the patient is maintained on
long-term cyclosporin immunosuppression, hypercho-
lesterolaemia may be a potential risk factor for car-
diovascular morbidity (16).
In our patients, prednisolone and cyclosporin together
with azathioprine were used for immunosuppression
after renal transplantation.
In the present study, serum total cholesterol concen-
trations were increased, and apolipoprotein A-I/apo-
lipoprotein B ratios were decreased in renal transplant
patients, compared with the controls. Thus, LDL
cholesterol concentrations were also increased. These
results are in agreement with studies indicating that
cyclosporin, either alone or with prednisolone, causes
a significant increase in LDL cholesterol after trans-
plantation.
In the light of these results, we think that LDL cho-
lesterol metabolism in renal transplant patients is
different from that in normal subjects, and that hy-
percholesterolaemia is a possible risk factor for car-
diovascular disease in these patients.
Triacylglycerol concentrations were significantly in-
creased in renal transplant patients compared with
those of the controls. Hypertriglyceridaemia, which
has started during the predialytic phase accelerates
during dialysis and continues after transplantation
(10, 18, 19). Apolipoprotein C-II is the activator of
lipoprotein lipase1), an enzyme that regulates triacyl-
glycerol metabolism, and apolipoprotein C-III is the
inhibitor of the same enzyme (20, 21). The apolipo-
protein C-II/apolipoprotein C-III ratio is a marker of
the regulation of lipoprotein lipase activity (2). De-
pressed activities of the lipoprotein lipase and hepatic
lipase result in reduced catabolism of triacylglycerol-
rich lipoproteins and thus a delay in the clearance of
*) Enzyme
Lipoprotein lipase (EC 3.1.1.34)
the remnants, so that the conversation of intermediate
density lipoprotein (IDL) — to low density lipopro-
tein (LDL) is impaired (2,10, 22). A variety of studies
have indicated that both impaired removal and in-
creased production of triacylglycerol-rich lipoproteins
contribute to the hypertriglyceridaemia of chronic
renal failure. More recent studies suggest that a de-
fective removal of triacylglycerol-rich lipoproteins in
such patients may be a more significant contributory
factor than increased production (23). This view is
supported by studies demonstrating reduced plasma
postheparin lipolytic activity, and decreased clearance
of triacylglycerols in chronic renal failure (23, 24).
This may be the cause of hypertriglyceridaemia in our
patients.
Apolipoprotein E is approximately equally distributed
between VLDL and HDL in normal plasma. It has
been shown that apolipoprotein E plays a role in the
pathogenesis of atherosclerosis (25, 26). Modulation
of smooth muscle cell proliferation and migration is
of particular importance in arterial wall pathophys-
iology (27). Heparin and heparin-like glycosamino-
glycans, added exogenously or produced by cells
within the artery wall, are potent inhibitors of smooth
muscle cell proliferation and motility (26). Apolipo-
protein E could play a role in smooth muscle cell
biology because of its ability to bind to heparin and
heparin-like glycosaminoglycans that are present in
the matrix of the arterial wall. The formation of
apolipoprotein E-heparin like complexes could mod-
ify the interaction of smooth muscle cells with the
matrix. Apolipoprotein E production may also par-
ticipate in smooth muscle cell differentiation (26).
Therefore, in our renal transplant patients, increased
apolipoprotein E concentrations may be related to
cardiovascular risk.
We also investigated plasma flbronectin concentra-
tions in transplantation patients and found no signif-
icant difference between those of the controls. The
presence of fibrinogen or fibrin antigen in athero-
sclerotic lesions has been confirmed by a number of
investigators (28). Fibrinogen forms complexes with
fibronectin and factor XIII, proteins playing a signif-
icant role in tissue repair (29, 30). Fibronectin is
essential for the formation of granulation tissue, for
chemotaxis of fibroblasts and for migration of smooth
muscle cells stimulated by platelet-derived growth fac-
tor. Preliminary data indicated that fibronectin can
be extracted from normal intima, from early prolif-
erative lesions and from mural thrombi (28). Further
studies are needed to determine the role of fibronectin
and factor XIII (transamidase) in the pathogenesis of
atherosclerotic lesions.
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These results show that atherosclerosis in renal trans-
plantation patients is associated with alterations in
lipoproteins and apolipoproteins contained in these
lipoproteins. On the other hand, according to our
findings, plasma fibronectin synthesized by vascular
endothelial cells seems not to be associated with the
atherosclerotic process. Further studies are in pro-
gress.
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